SCHEMBL29173582

SCHEMBL29173582

CNc1nc(Nc2ccc(N3CCOCC3)cc2)c(C(=O)O)nc1-c1cncc2c1ncn2C

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PIM1 P11309 2/20 0.41
▸ EML4 Q9HC35 3/20 0.40
▸ ALK Q9UM73 3/20 0.40
▸ CDK2 P24941 4/20 0.38
▸ CCNA2 P20248 3/20 0.38
▸ AURKA O14965 2/20 0.38
▸ CCNA1 P78396 2/20 0.38
▸ RET P07949 2/20 0.38
▸ ROS1 P08922 2/20 0.38
▸ FLT3 P36888 2/20 0.38
▸ CDK4 P11802 1/20 0.38
▸ CCND3 P30281 1/20 0.38
▸ CDK6 Q00534 1/20 0.38
▸ JAK2 O60674 3/20 0.38
▸ SYK P43405 2/20 0.38
▸ JAK3 P52333 1/20 0.38
▸ IGF1R P08069 2/20 0.37
▸ STAT6 P42226 1/20 0.37
▸ PKMYT1 Q99640 2/20 0.37
▸ INSR P06213 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24943791 0.93 EML4 (0.48) EML4ALKCDK2CCNA2AURKA
SCHEMBL29173512 0.92 PKMYT1 (0.40) PIM1EML4ALKCDK2CCNA2
SCHEMBL30206202 0.92 PKMYT1 (0.40) PIM1EML4ALKCDK2CCNA2
SCHEMBL29173501 0.91 PIM1 (0.42) PIM1EML4ALKCDK2CCNA2
SCHEMBL29173586 0.90 PIM1 (0.41) PIM1EML4ALKCDK2CCNA2
SCHEMBL29173491 0.90 LRRK2 (0.44) PIM1ALKCDK2AURKARET
SCHEMBL24944378 0.90 EML4 (0.46) EML4ALKCDK2CCNA2AURKA
SCHEMBL30206219 0.89 PIM1 (0.46) PIM1EML4ALKCDK2CCNA2
SCHEMBL29173508 0.89 PIM1 (0.46) PIM1EML4ALKCDK2CCNA2
SCHEMBL29173608 0.89 PKMYT1 (0.38) PIM1EML4ALKCDK2CCNA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4373817-B1 SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER ASTRAZENECA AB (SE) 2025-05-21 — — EP disclosed
US-20240374606-A1 SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER ASTRAZENECA AB (SE) 2024-11-14 — — US disclosed
EP-4373817-A1 SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER Astrazeneca AB (SE) 2024-05-29 — — EP disclosed
CN-117693503-A Substituted pyrazine-2-carboxamides as HPK1 inhibitors for the treatment of cancer 阿斯利康(瑞典)有限公司 2024-03-12 — — CN disclosed
WO-2023001794-A1 SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER ASTRAZENECA AB (SE) 2023-01-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240374606-A1 SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER PDXK, PGK1, PGK2 PIM1 480/4885EML4 2189/4885ALK 2002/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback